Replies to post #4362 on Antares Pharma, Inc. (ATRS)

[CYRXorbust]

i would be curious to hear his revised near term price target (currently $5.50) given the Pfizer announcement. also what is a reasonable PE ratio once we hit profitability

concerned at their lack of experience running their own sales team. cash burn will increase and if Makena royalties do not cover our next earnings report might show us moving backwards on EPS. lets hope EPI and XYO carry us thru and we are all too drunk to notice

[H2R]

Xyosted Sept. 29 PDUFA less than a month away...
Wonder if we'll see a PPS ramp up to that date.